Industry
From U.S. (Toll Free) : +16467917070    |   UK : +442030260021     |    sales@businessmarketinsights.com

Europe Smart Inhalers Market to 2027 - Regional Analysis and Forecasts by Product (Nebulizers and Inhalers); Disorder (Chronic Obstructive Pulmonary Disease (COPD), and Asthma); End User (Home-Care Settings and Hospitals & Clinics), and Country

Report Code :  TIPRE00006804
No. of Pages :  111
Published Month :  Oct 2019
Category :  Life Sciences
$299 per month

Best Plan
  • All Reports in One Industry
  • All Reports Read Access
  • Subscription Duration : 12 Months
  • Monthly New Reports Added
  • $1200 Yearly Saving

The Europe smart inhalers market is expected to reach US$ 2,129.61 Mn in 2027 from US$ 302.40 Mn in 2018. The market is estimated to grow with a CAGR of 24.9% from 2019-2027.

 

The growth of the smart inhalers market is driven by the factors such as, growing geriatric population rising prevalence of COPD and asthma, along with rising awareness regarding the medical condition. However, the market is likely to get impacted due to risks associated with cyber threats limited knowledge regarding the use of smart inhalers.

 

With rapid urbanization there has been growth in various adverse factors that have led to the growth of respiratory diseases across the Europe. Some of the factors leading to growth in the number of asthma and COPD cases across the Europe are rise in air pollution levels and increasing smoking habits.

 

The rise in air pollution levels has been a matter of rising concern in developed as well as developing economies. As per data published by the World Health Organization (WHO) released during May 2018, 9 out of 10 individuals are believed to breathe air containing high levels of pollutants. Data published by WHO reveals that approximately 7 million people die every year due to exposure to fine particles present in polluted air, which penetrate deep into lungs and the cardiovascular system. This leads to various diseases such as lung cancer, pneumonia, chronic obstructive pulmonary diseases and respiratory infections, among others. Studies reveal, above 90% of air pollution-related deaths worldwide occur in low- and middle-income countries of the Eastern Mediterranean, European regions. According to world health organization (WHO), about 21,000 premature deaths per year in European region because of air pollution like Ozone pollution courses breathe difficulties, triggers asthma symptoms, and causes lung and heart diseases. Additionally increasing indirect effects of air pollution like growing climate change, because of transport is the fastest growing source of fossil-fuel emissions of carbon dioxide (CO2) which is a largest contributor of the climate change. As per data published by World Health Organization (WHO) Some 40 million people in the 115 largest cities in the European Union (EU) are exposed to air exceeding WHO air quality guideline values for at least one pollutant. Children living near roads with heavy-duty vehicle traffic have twice the risk of respiratory problems as those living near less congested streets. Hence, the rising levels of air pollution coupled is anticipated to drive the demand for smart inhalers market during the forecast period.

 

In 2018, the inhalers segment held a largest market share of the smart inhalers market, by product. The inhalers is expected to dominate its market share in 2027 owing to the increasing mortality rate of asthma. The inhalers segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.

 

UK is expected to lead the market in the Europe region because the growing prevalence of asthma and COPD Across the country. According to the data published in Asthma UK, in 2016 to 2017 there were 77,124 admissions to hospital for asthma in the UK and in 2017 1,484 people in the UK died from an asthma attack in the UK. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the Europe region during the forecast period.

 

Italy Smart Inhalers Market Revenue and Forecasts to 2027 (US$ Mn)


 

EUROPE SMART INHALERS - MARKET SEGMENTATION

 

By Product

  • Inhalers
  • Nebulizers

 

By Disorder

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)

 

By End User

  • Home-care Settings
  • Hospitals & Clinics

 

By Geography

  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy

 

Company Profiles

  • GlaxoSmithKline plc
  • Adherium Ltd.
  • Vectura Group plc
  • Novartis AG
  • Findair Sp. z o. o.
  • Cohero Health
  • Crux Product Design Ltd
  • Teva Pharmaceuticals
  • 3M
  • Amiko Digital Health Limited

 

The List of Companies - Europe Smart Inhalers Market

  1. GlaxoSmithKline plc
  2. Adherium Ltd.
  3. Vectura Group plc
  4. Novartis AG
  5. Findair Sp. z o. o.
  6. Cohero Health
  7. Crux Product Design Ltd
  8. Teva Pharmaceuticals
  9. 3M
  10. Amiko Digital Health Limited

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe smart inhalers market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the Euroep smarts inhaler Market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth the Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.